Home / Medical Care in China / Hematology / leukemia

Medical Care in China

leukemia
Treatment in China

Provide a clear and complete coordinated pathway from expert assessment to treatment and rehabilitation.

Get a Care Plan and Cost Estimate

The coverage of blood diseases is broadincluding anemia, leukemia, lymphoma, and myeloma.

Precise blood diagnosisclarifies the condition through bone marrow, molecular and genetic examinations.

Cell therapy selectionCAR-T and other therapies are evaluated for eligible patients.

Transplantation therapy supportcovers hematopoietic stem cell transplantation and related management.

Condition Guide

About leukemia

Understand the condition, common triggers and treatment options that may require specialist assessment.

Disease Introduction

Leukemia is a hematologic malignancy caused by the malignant clonal proliferation of hematopoietic stem and progenitor cells. Based on cell origin, it is classified into acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL, more common in children), and chronic myeloid leukemia (CML). Typical manifestations include anemia, bleeding, fever and infection, bone pain, and enlargement of the liver, spleen, and lymph nodes. The cure rate for childhood beta-angiocarcinoma (B-ALL) with standard chemotherapy exceeds 90%. Adults and those with relapsed or refractory conditions require comprehensive treatment including targeted therapy, immunotherapy, and transplantation.

Cutting-edge high-precision diagnostic and treatment technologies

CAR-T Precision Targeting : CD19 and CD19/CD22 dual-target CAR-T cell therapies have significantly improved the complete remission rate of relapsed and refractory B-ALL; CD7 CAR-T is used for T-ALL/lymphoblastic lymphoma, and universal and gene-editing products are constantly being developed.
Domestic CAR-T approved : In November 2025, the first domestically developed CAR-T product for childhood leukemia, "Pukiolensai Injection", was approved by the NMPA. It is the world's first humanized design product targeting the same target (CD19), filling the gap in the treatment of children and adolescents.
AML Targeted Stratification : FLT3 inhibitors (such as giretinib), IDH1/2 inhibitors, and Venecella combined with demethylation regimens are used for precise treatment based on molecular subtypes, which significantly improves AML remission rates and survival.
Bispecific antibody bridging transplantation : Bispecific antibodies such as belintolimab are used for minimal residual disease positive or relapsed ALL. After clearing residual lesions, hematopoietic stem cell transplantation is performed to reduce the risk of relapse.
Transplantation to consolidate radical cure : Allogeneic hematopoietic stem cell transplantation remains the most important radical cure for high-risk/relapsed leukemia, with continuous progress in donor selection, pretreatment optimization, and post-transplant maintenance therapy.

Care Overview

leukemia Treatment in China

The medical team will develop a personalized protocol based on the pathology type, stage, genetic test, previous treatment history, and the patient's physical condition.

1. Standard practice for childhood ALL : Stratified by risk level, multi-drug combination chemotherapy is administered. The cure rate for standard-risk children exceeds 90%. Close monitoring of minimal residual disease after chemotherapy guides subsequent treatment.
2. Relapsed/Refractory Immunotherapy : For relapsed/refractory B-ALL, CD19/CD22 CAR-T or berintoumab dual anti-inflammatory therapy should be prioritized, followed by bridging transplantation for consolidation after remission.
3. Long-term targeted therapy for CML : Tyrosine kinase inhibitors (imatinib and second-generation TKIs) are the first choice for chronic myeloid leukemia. Regular monitoring of BCR-ABL quantification is conducted to explore deep molecular remission or even drug discontinuation.
4. AML induction stratification : AML is induced by intensive chemotherapy or a combination of veneclade and other regimens based on age, physical condition, karyotype and gene mutation. After remission, consolidation chemotherapy or transplantation is performed.
5. Comprehensive support management : Standardized component blood transfusion, anti-infection, and management of granulocytopenia and cytokine release syndrome during treatment, and multidisciplinary collaboration to reduce treatment-related mortality.

1. Significantly improved cure rate : The cure rate for childhood ALL exceeds 90%, the long-term survival rate for adult leukemia continues to improve, and some subtypes have reached the level of chronic disease management.
2. The revolution in immunotherapy : CAR-T and dual anti-inflammatory drugs have transformed relapsed and refractory leukemia from a hopeless situation to one where remission is possible, bridging transplantation is possible, and long-term survival is achievable.
3. Targeted, less toxic, and more effective : Targeted drugs such as FLT3 and IDH are more selective and have fewer side effects than traditional chemotherapy, making them suitable for the elderly and those who cannot tolerate intensive chemotherapy.
4. Accelerated Accessibility of Domestic Products : Domestic CAR-T products have been approved for marketing, and cell therapy has shifted from import dependence to independent research and development, with continuous improvement in cost and accessibility.
5. Guaranteed radical cure through transplantation : With mature allogeneic transplantation technology and post-transplant maintenance and monitoring, the chances of long-term disease-free survival for high-risk patients are significantly increased.

Network of partner hospitals

Recommended Hospitals

Selected leading medical centers with strong specialties and international patient services.

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Beijing · Partner Hospital

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Hematology

The institute is the supporting unit of the National Clinical Research Center for Hematological Diseases, the National Stem Cell Engineering Technology Research Center, and the Stem Cell Medicine Center of the Chinese Academy of Medical Sciences. It is also the executive department of the World Federation of Hemophilia (China), the supporting unit of the National Hemophilia Case Information Management Center, and is leading the establishment of the National Quality Control Center for Hematology. For many consecutive years, it has ranked first in the Fudan University ranking of hematology disciplines, and its CAR-T cell therapy center for hematological diseases ranks second in the country.

Year Founded: 1957
Beds: 1540

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai · Partner Hospital

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

OncologyHematologyGastroenterologyUrologyInternal MedicineSurgeryOrthopedics

Ruijin Hospital consistently ranks among the top four hospitals in China according to the comprehensive hospital rankings released by the Fudan University Hospital Management Institute. It is a national medical center construction unit and possesses national-level platforms such as the National Clinical Research Center for Metabolic Diseases and the National Clinical Research Center for Hematological Diseases. The hospital currently has four key disciplines designated by the Ministry of Education (Hematology, Endocrinology and Metabolic Diseases, Cardiology, and Neurology), 22 national key clinical specialties, and one national key laboratory for medical genomics. The hospital has been awarded the title of National Civilized Unit four times consecutively and has received honors such as the National May 1st Labor Medal and the National Advanced Collective of the Health System. It is also a national demonstration unit for integrated traditional Chinese and Western medicine.

Year Founded: 1907
Beds: 5100

Southern Medical University Southern Hospital

Guangzhou · Partner Hospital

Southern Medical University Southern Hospital

Organ TransplantHematologyInternal MedicineCosmetic Surgery

The hospital is a national regional trauma medical center jointly constructed by the provincial and national governments, a national project unit for improving the diagnosis and treatment capabilities of difficult and complex diseases (tumors), a national regional TCM (rheumatology) treatment center, a national emergency medical rescue base, and one of the first key construction units in Guangdong Province's "Peak Climbing Plan" for high-level hospitals. It boasts 5 national key disciplines, 17 national key clinical specialties, and 4 national key clinical specialty construction projects. In the 2023 national public hospital performance evaluation, it ranked in the A+ category. In authoritative domestic hospital rankings, the hospital consistently ranks among the top 15 to 20 comprehensive hospitals nationwide, with more than ten specialties, including nephrology, infectious diseases, plastic surgery, hematology, pathology, and gastroenterology, ranking in the top ten or receiving nominations.

Year Founded: 1941
Beds: 2225

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan · Partner Hospital

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

HematologyCardio-CerebrovascularUrology

The hospital ranks 9th nationwide in the Fudan University China Hospital Specialty Ranking, making it one of the strongest hospitals in Central China. Its specialties, including heart transplantation, hematology, ultrasound, nuclear medicine, anesthesiology, and cardiovascular surgery, are among the top in the country. In particular, its nuclear medicine department has consistently ranked among the top two in Fudan University's specialty rankings for many years, and its heart transplant volume has ranked first in the country for many consecutive years. The hospital is a national drug clinical trial institution and a national stem cell clinical research institution, boasting strong research capabilities.

Year Founded: 1866
Beds: 6000

Leading Specialists

Trusted Expertise Across Leading Specialties

Feng Ru

Professor, Chief Physician, Doctoral Supervisor, Deputy Director of Department, Head of Lymphoma Subspecialty

Hematology

-Research areas : pathogenesis, diagnosis and treatment of lymphoma and multiple myeloma, targeted immunotherapy, and leukemia. - Cutting-edge technologies: Dynamic monitoring of MRD for lymphoma and myeloma, and clinical research on new drugs for relapsed and refractory lymphomas. - Areas of expertise: Hodgkin's/non-Hodgkin's lymphoma, multiple myeloma, plasma cell diseases, lymphoma, leukemia. - Academic Highlights & Value: Visiting scholar experience in the United States and Japan; presided over multip

Affiliated Hospital Southern Medical University Southern Hospital

Sun Jing

Professor, Chief Physician, Doctoral Supervisor, Deputy Director of Department, Director of Hemophilia Center

Hematology

-Research areas : Hematopoietic stem cell transplantation, bleeding disorders, and hemophilia diagnosis and treatment - Cutting-edge technologies: unrelated hematopoietic stem cell transplantation, hemophilia inhibitor immune tolerance induction program/comprehensive diagnosis and treatment of hemophilia and inhibitor management (the largest hemophilia center in South China), prevention and treatment of transplant complications. - Areas of expertise: Hemophilia, von Willebrand disease, platelet disorders,

Affiliated Hospital Southern Medical University Southern Hospital

Zhang Xiaobing

Researcher, doctoral supervisor, head of the cell gene transformation platform

Hematology

Research areas : gene editing, CAR vector design, iPSC, LNP delivery technology; Cutting-edge technologies: CRISPR gene editing CAR cells, GMP construction of lentiviral vectors; Areas of expertise: CAR vector development, gene therapy; Academic highlights: National high-level talent, multiple cell therapy invention patents; Core value: Supporting the research and clinical translation of underlying vector technologies for CAR-T and gene therapy.

Affiliated Hospital Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Zhao Weili

Chief Physician, Level 2 Professor, Doctoral Supervisor, Director of Shanghai Institute of Hematology, Vice President of Ruijin Hospital

Hematology

-Research areas : lymphoma immunotherapy, CAR-T cell therapy clinical research, and real-world CAR-T studies in Asian populations. - Cutting-edge technologies: CAR-T stratified treatment system for relapsed and refractory large B-cell lymphoma; CAR-T adverse reaction MDT management model. - Areas of expertise: Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, and other B-cell non-Hodgkin lymphomas. - Academic Highlights: Led a multicenter real-world study of CAR-T th

Affiliated Hospital Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Liu Qifa

Level 2 Professor, Chief Physician, Doctoral Supervisor, Academic Leader, Director of the Institute of Hematology

Hematology

Research areas : Molecular pathogenesis of leukemia, hematopoietic stem cell transplantation, tumor immunotherapy, and prevention and treatment of infections in immunocompromised hosts. - Cutting-edge technologies: Haploidentical hematopoietic stem cell transplantation; MICM precision stratification therapy for leukemia; precision stratification therapy for acute leukemia (rewriting the NCCN/ELN guidelines); combined haploidentical and umbilical cord blood transplantation (Lancet RCT); MSC prevention of G

Affiliated Hospital Southern Medical University Southern Hospital

Li Junmin

Head of Hematology

Hematology

Research areas : hematologic malignancies and hematologic immune diseases; construction of CAR-T clinical research system. Cutting-edge technology: creation of translational medicine wards and CAR-T clinical trial screening system. Specializes in treating: acute myeloid leukemia, multiple myeloma, and lymphoma. Academic Highlights: Led the establishment of China's first translational medicine ward in hematology; emphasized that CAR-T "is a novel immunotherapy that acts on the tumor microenvironment and ha

Affiliated Hospital Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Patient Stories

See the Next Step Through Patient Journeys

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the

CASE 01

PATIENT JOURNEY

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the "Silent Killer"

HematologyCardio-Cerebrovascular

Patient records Name: Carlos Silva Age: 70 Nationality: Brazil (São Paulo) Diagnosis: Lower extremity arteriosclerosis obliterans (Rutherford grade 4, long segment occlusion of the left superficial femoral artery, rest pain) Treatment Hospital: Department of Vascular Surgery, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Mr. Carlos is a passionate samba dancer who, even in his seventies, still enjoys swaying to the music on the streets of Rio. However, for the past six mo

View case details →

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible

CASE 02

PATIENT JOURNEY

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible "cure" in China.

OncologyHematology

Patient records Name: Sarah Age: 32 Nationality: Australia Diagnosis: Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), non-germinal center type (non-GCB), CD19 positive, relapsed after autologous stem cell transplantation. Treatment Hospital: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin) In the field of cancer treatment, CAR-T cell therapy is hailed as "living medicine," bringing hope of a cure to patients with relapsed or refractory hemat

View case details →

CASE 03

PATIENT JOURNEY

When CAR-T "Failed": How a Singaporean child found a backup plan in China Patient records

Hematology

Name: Ethan (pseudonym) Age: 8 years old Nationality: Singapore Diagnosis: Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), CD19-negative relapse after CD19 CAR-T therapy. Treatment Hospital: Shanghai Children's Medical Center In the field of childhood leukemia treatment, CAR-T cell therapy has brought hope to countless families. But when this "living drug" also fails, patients' families face an abyss of near despair. Ethan's story tells how we helped a family find a "backup plan" with

View case details →

Service Process

A clear, coordinated process for efficient cross-border care

01
Pre-Visit Services
Contact us for help organising and translating medical records, planning consultations, and finding suitable hospitals and specialists.
02
Remote Consultations
A remote consultation helps establish an initial approach to diagnosis and treatment, with a cost estimate available within 48 hours.
03
Travel Arrangements
We assist with visa applications, book flights and hotel or apartment accommodation, and arrange airport pick-up, private transport and check-in.
04
Comprehensive Support in China
We accompany you to medical appointments and provide interpreting services, help arrange specialist consultations or surgery, assist with hospital admission and discharge, and help settle medical bills.
05
Post-Visit Services
We assist with notarisation of medical expense documents, airport drop-off, organisation and translation of medical records, remote rehabilitation guidance, and coordination of international referrals.

Next Step

Get a Care Plan
and Cost Estimate.

Tell us about your diagnosis and needs, and our team will help screen the right hospital and explain the next steps.

Email:goldentcm@163.com

leukemia
Treatment in China

About leukemia

leukemia Treatment in China

Recommended Hospitals

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Southern Medical University Southern Hospital

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Trusted Expertise Across Leading Specialties

Feng Ru

Sun Jing

Zhang Xiaobing

Zhao Weili

Liu Qifa

Li Junmin

Chen Saijuan

Pan Jing

Wang Jianxiang

Zhang Ruidong

Wu Runhui

Zhang Rui

Zhai Xiaowen

Shen Shuhong

See the Next Step Through Patient Journeys

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the "Silent Killer"

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible "cure" in China.

When CAR-T "Failed": How a Singaporean child found a backup plan in China Patient records

A clear, coordinated process for efficient cross-border care

Pre-Visit Services

Remote Consultations

Travel Arrangements

Comprehensive Support in China

Post-Visit Services

Get a Care Plan
and Cost Estimate.

Get a Care Plan and Estimate

leukemiaTreatment in China

leukemia Treatment in China

Recommended Hospitals

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Southern Medical University Southern Hospital

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Trusted Expertise Across Leading Specialties

See the Next Step Through Patient Journeys

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the "Silent Killer"

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible "cure" in China.

When CAR-T "Failed": How a Singaporean child found a backup plan in China Patient records

A clear, coordinated process for efficient cross-border care

Pre-Visit Services

Remote Consultations

Travel Arrangements

Comprehensive Support in China

Post-Visit Services

Get a Care Planand Cost Estimate.

Get a Care Plan and Estimate

leukemia
Treatment in China

Get a Care Plan
and Cost Estimate.